Evidence map›Paper›PMID 39028186›Full record

ArticlemAbs

Modulation of the high concentration viscosity of IgG

Joel Heisler, Daniel Kovner, Saeed Izadi, Jonathan Zarzar, Paul J Carter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Fab-Fc and Fab-Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgGProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joel HeislerDepartment of Antibody Engineering, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0002-2703-3035
Daniel KovnerDepartment of Pharmaceutical Development, Genentech, Inc, South San Francisco, CA, USA.
Saeed IzadiDepartment of Pharmaceutical Development, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0003-4206-8559
Jonathan ZarzarDepartment of Pharmaceutical Development, Genentech, Inc, South San Francisco, CA, USA.
Paul J CarterDepartment of Antibody Engineering, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0001-7854-062X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The self-association of therapeutic antibodies can result in elevated viscosity and create problems in manufacturing and formulation, as well as limit delivery by subcutaneous injection. The high concentration viscosity of some antibodies has been reduced by variable domain mutations or by the addition of formulation excipients. In contrast, the impact of Fc mutations on antibody viscosity has been minimally explored. Here, we studied the effect of a panel of common and clinically validated Fc mutations on the viscosity of two closely related humanized IgG

Indexed as

Immunoglobulin Fc FragmentsImmunoglobulin GMutationOmalizumabTrastuzumabHumansImmunoglobulin Fab FragmentsViscosityImmunoglobulin Fab FragmentsImmunoglobulin Fc FragmentsImmunoglobulin GOmalizumabTrastuzumabIntermolecular interactionsintramolecular interactionsmolecular dynamicsrheologyself-associationsubcutaneous deliveryviscosity

Identifiers

PMID39028186
PMCPMC11262234

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.